相关实验视频
Updated: Sep 12, 2025

02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
5.3K
发现和开发一种针对α2B adrenoceptor的口服止痛药
Masayasu Toyomoto1,2,3,4, Takashi Kurihara5, Takayuki Nakagawa6,7
1Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
概括
一种新型化合物,ADRIANA,作为α-2B上腺激素抗剂,促进上腺素的释放,并通过α-2A通路提供非阿片类药物止痛,没有心血管副作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 诺拉丁上腺素通过α2A-上腺素受体调节疼痛.
- 现有的α2-上腺激动剂 (克罗尼丁,德克斯梅德托米丁) 具有止痛作用,但受到心血管风险的限制.
研究的目的:
- 确定一种针对非阿片类药物止痛的α2B-上腺体受体的新型化合物.
- 研究ADRIANA在疼痛模型中的作用机制和疗效.
主要方法:
- 作为α2B亚型特异性抗剂的 (Z) - 1 - 3 - 乙烯 - 5 - 博 - d - 醇 - 2 - 3 - H - 伊利丁 - - - 2 - 一 (ADRIANA) 的表征.
- 评估ADRIANA对小鼠脊柱背角中诺亚上腺素释放的影响.
- 在小鼠和非人类灵长类动物疼痛模型中评估ADRIANA的止痛和心血管作用.
- 分析ADRIANA在α2B上腺受体淘汰小鼠中的疗效.
主要成果:
- 特别地,ADRIANA促进了脊柱背部角中诺亚上腺素的释放.
- 口服的ADRIANA在不同物种的各种可感应性疼痛模型中表现出强大的止痛作用.
- 治疗ADRIANA并没有引起显著的心血管影响 (高血压/低血压,心肌梗塞).
- 在缺乏α2B上腺受体的小鼠中,ADRIANA的止痛作用不存在.
结论:
- 特定于α2B亚型的抗剂ADRIANA激活了α2A依赖的下降疼痛抑制途径.
- 阿德里安娜是一种有前途的非阿片类止痛药,向α2B上腺受体.
- 这一发现为疼痛管理提供了潜在的治疗策略,而不会产生当前治疗的不良影响.
相关概念视频
Analgesia and Pain Management
793
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
793
Opioid Analgesics: Synthetic and Semisynthetic Opioids
436
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
436
Adrenergic Receptors: ɑ Subtype
1.8K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
972
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
972
Adrenergic Agonists: Direct-Acting Agents
1.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.0K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.0K

